Results 251 to 260 of about 80,161 (286)
Some of the next articles are maybe not open access.
Diabetes & Metabolism, 2022
PURPOSE Type 2 diabetes (T2D) is an important risk factor for glaucoma, and sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to protect the optic nerves.
S. Shao +8 more
semanticscholar +1 more source
PURPOSE Type 2 diabetes (T2D) is an important risk factor for glaucoma, and sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to protect the optic nerves.
S. Shao +8 more
semanticscholar +1 more source
Current pharmaceutical design
Atherosclerotic Cardiovascular Disease (ASCVD) is still one of the leading causes of death globally, with Coronary Artery Disease (CAD) being the most prevalent form of ASCVD.
P. Karakasis +7 more
semanticscholar +1 more source
Atherosclerotic Cardiovascular Disease (ASCVD) is still one of the leading causes of death globally, with Coronary Artery Disease (CAD) being the most prevalent form of ASCVD.
P. Karakasis +7 more
semanticscholar +1 more source
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2019Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh +8 more
openaire +5 more sources
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
Clinical Nephrology, 2017Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou +2 more
openaire +2 more sources
The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review
AnaesthesiaSodium‐glucose co‐transporter 2 inhibitors are a novel class of antihyperglycaemic drugs used in the management of type 2 diabetes, that improve glycaemic control, cardiovascular outcomes and promote weight loss.
P. Stewart +3 more
semanticscholar +1 more source
Sodium-glucose transporter inhibitors 2 in acutely ill patients
Current Opinion in Clinical Nutrition & Metabolic CarePurpose of review Sodium–glucose cotransporter-2 inhibitors (SGLT2i) have rapidly become central to the management of heart failure and chronic kidney disease. Their widespread use now extends into the peri-acute and critical-care setting, raising questions about whether these agents should be continued or ...
Fernando G, Zampieri +2 more
openaire +2 more sources
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources
Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor
Diabetes/Metabolism Research and Reviews, 2016AbstractBackgroundThe effect of sodium glucose transporter 2 (SGLT‐2) inhibitors is dependent on the glomerular filtration rate. It has been reported that caffeine intake increases glomerular filtration rate. However, the effect of caffeine intake on urinary glucose excretion in patients who take SGLT‐2 inhibitors is unclear.MethodsSix patients with ...
Yoshitaka Hashimoto +8 more
openaire +2 more sources
Corticosteroids/sodium glucose transporter-2 inhibitors
Reactions Weekly, 2020openaire +1 more source